Abstract 298P
Background
Adenoid cystic carcinoma (ACC) of the breast is a rare subtype of breast cancer that is characterized by more favorable outcomes than extramammary ACC. Its rarity makes the establishment of standardized treatment protocols challenging. This study aimed to develop a machine learning (ML)-based prognostic model that improves the accuracy of survival rate predictions for patients with ACC.
Methods
The SEER database provided the data used for this study’s analysis (2000–2020). Patients who met any of the following criteria were excluded: diagnosis not confirmed by histology, previous history of cancer or other concurrent malignancies, or unknown data. To identify prognostic variables, we conducted Cox regression and constructed prognostic models using five ML algorithms to predict the 5-year survival. Patient records were randomly divided into training (70 %) and validation (30 %) sets. A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of the ML models.
Results
The study population comprised 1212 patients. The median patient age was 60 years, and the median tumor size was 1.9 cm. The largest racial group was white (79.5 %). Furthermore, most cases were localized (95.1%), T1 (56.2%), and N0(96.4%). The most common type of surgery performed was partial mastectomy (74.8%). Analysis of the therapeutic options revealed significantly different survival rates. While surgery + RT had a 94.9% overall 5-year survival rate, surgery alone had a rate of 91%. For surgery + CTX, the survival rate was 83.5% and 80.1% for surgery + CTX + RT. The corresponding cancer specific survival rates were 68.5%, 63.5%, 75%, and 70.8%, respectively. The ML models demonstrated strong predictive capabilities, with random forest classifier performing the best. ML identified that the most contributing factors were age, followed by the N component of the AJCC stage and ER status.
Conclusions
ML approaches provide superior predictive performance compared with traditional statistical methods. The developed models can significantly aid personalized treatment planning and improve the clinical outcomes of patients with ACC.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Early detection of metastatic disease in asymptomatic early-stage breast cancer patients using imaging: A cross-sectional analytic study at a tertiary hospital
Presenter: John kelvin Lalusis
Session: Poster session 14
313P - A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
Presenter: Jae Pak Yi
Session: Poster session 14
314P - The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Presenter: Mark Magbanua
Session: Poster session 14
315P - Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer
Presenter: Oscar Danielsson
Session: Poster session 14
316P - Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials
Presenter: Magdalena Rios Romero
Session: Poster session 14
317TiP - A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
Presenter: Zhimin Shao
Session: Poster session 14
318TiP - Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
Presenter: Fleur Louis
Session: Poster session 14
319TiP - NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
Presenter: Etienne Bastien
Session: Poster session 14
321P - Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study
Presenter: Yasuaki Sagara
Session: Poster session 14
322P - Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Presenter: Alexandra Thomas
Session: Poster session 14